PubRank

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Clinical Trial ID NCT02475915

PubWeight™ 2.27‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02475915

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009 8.45
2 Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012 7.76
3 Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013 6.14
4 Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012 3.69
5 Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009 2.68
6 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
7 Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014 2.10
8 Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012 1.66
9 Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011 1.42
10 Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009 1.39
11 Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014 1.30
12 A cure for HIV: where we've been, and where we're headed. Lancet 2013 1.00
13 Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 2013 0.94
14 Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol 2011 0.88
15 Intermittent therapy for the treatment of chronic HIV infection. AIDS 2007 0.81
16 Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis 2016 0.80
17 Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. AIDS 2015 0.77
18 The therapeutic potential of epigenetic manipulation during infectious diseases. Pharmacol Ther 2016 0.75
Next 100